Vivo Bio Tech Approves FY26 Audited Results & Reappoints Director

Vivo Bio Tech Ltd's board approved the audited standalone and consolidated financial results for the fourth quarter and year ended March 31, 2026. They also approved the re-appointment of Mr. Kalyan Ram Mangipudi as a Whole-time Director for 5 years, subject to shareholder approval. Additionally, the board approved material related party transactions, also subject to shareholder approval via postal ballot, and the appointment of a consultant/advisor for a proposed Scheme of Arrangement/Amalgamation.